Solasia Pharma KK
Manufacturing · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sumitomo Fudosan Shiba-Koen Tower 4th fl...Phone Number
+81 358438045Website
www.solasia.co.jpRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Solasia Pharma KK
Solasia Pharma K.K. is dedicated to developing better pharmaceuticals for patients facing cancer, aiming to contribute to their healthy lives and future. The company specializes in creating a wide range of drugs to address unmet medical needs in oncology, leveraging deep expertise and a strong understanding of patient challenges. With a small, agile team, Solasia is able to make quick decisions and respond flexibly to complex issues that larger companies may find difficult to tackle. Their product portfolio includes treatments for chemotherapy-induced nausea and vomiting, as well as supportive care for cancer treatment side effects.Explore more
Solasia Pharma KK Org Chart
TM
Chief Financial Officer
YY
Representative Director and President
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Solasia Pharma KK your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Solasia Pharma KK
Check if Solasia Pharma KK has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Solasia Pharma KK recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Solasia Pharma KK had a recent Job posting/layoffs
Product Launch: Get notified when Solasia Pharma KK launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Solasia Pharma KK has new funding data
Solasia Pharma KK, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Solasia Pharma KK is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Solasia Pharma KK as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Solasia Pharma KK is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Solasia Pharma KK is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Solasia Pharma KK.
Solasia Pharma KK Tech Stack
A closer look at the technologies used by Solasia Pharma KK
Solasia Pharma KK News & Media
Solasia acquires episil oral liquid business from Camurus
Lund, Sweden and Tokyo, Japan — 8 July 2022 — Camurus AB (NASDAQ STO: CAMX, hereinafter “Camurus”) and Solasia Pharma K.K. (TSE: 4597, hereinafter “Solasia”) today jointly announced that they have entered into an agreement in which Solasia has acquired episil[®] oral liquid (episil, SP-03, hereinafter “episil”), a unique and effective treatment for intra-oral pain associated with e.g. oral mucositis, from Camurus and been granted relevant IP rights. Under the terms of the agreement, SolasiaBrand Institute Partners on Brand Name Development for Treatment of Relapsed or Refractor Peripheral T-Cell Lymphoma Now Approved by Ministry of Health, Labour and Welfare (Japan)
MIAMI, July 5, 2022 /PRNewswire/ -- Brand Institute is proud to announce its work with Solasia Pharma K.K. ("Solasia") in developing the brand name DARVIAS®. DARVIAS®, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the...Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter “PTCL”) by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co., Ltd.Solasia und Nippon Kayaku geben Lizenzvereinbarung in Japan für neuen Medikamentenkandidaten DARINAPARSIN (SP-02) bekannt
TOKIO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKIO: 4597; Hauptsitz: Tokio, Japan; Präsident und CEO: Yoshihiro Arai; im Folgenden kurz „Solasia“) und Nippon Kayaku Co., Ltd. (TOKIO: 4272; Hauptsitz: Tokio, Japan; Präsident: Atsuhiro Wakumoto), haben heute gemeinsam den Abschluss einer Lizenzvereinbarung über die Vermarktungsrechte für Darinaparsin (generischer Name, Entwicklungscode: SP-02) in Japan bekannt gegeben (im Folgenden kurz „diese Vereinbarung“). Darinaparsin ist ein Medikamentenkand
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Solasia Pharma KK
Sign Up For FreeTo access detailed company insights
Solasia Pharma K.K. is dedicated to developing better pharmaceuticals for patients facing cancer, aiming to contribute to their healthy lives and future. The company specializes in creating a wide range of drugs to address unmet medical needs in oncology, leveraging deep expertise and a strong understanding of patient challenges. With a small, agil... Read More
